Granules India update on USFDA inspection at Gagillapur facility
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
The initiative aims to empower individuals to take proactive steps towards monitoring their health
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
This acquisition marks Max Healthcare's entry into Lucknow
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Subscribe To Our Newsletter & Stay Updated